7 results
The research hypothesis for this study is that concurrent durvalumab plus SoC chemotherapy will be more effective than placebo plus SoC chemotherapy for the treatment of MRD+ patients who have undergone complete resection of stage II-III NSCLC when…
To evaluate whether a faecal calprotectin guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD compared with an unchanged dosing interval.
Primary Objective:• To compare the progression-free survival (PFS) of patients randomized to mirvetuximab soravtansine (MIRV) vs. Investigator*s choice of chemotherapy (IC Chemo) Key Secondary Objectives:• To compare the objective response rate (ORR…
Primary objectives:•To determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RPTD) of ABBV-155 administered as monotherapy (Part 1a)•To determine MTD and RPTD of ABBV-155 administered in combination with paclitaxel or docetaxel (…
Possibly, outcomes of treatment of irresectable squamous cell carcinoma of the esophagus can be improved by adding bintrafusp alfa to treatment with definitive chemoradiotherapy. As a first step we aim to know whether the addition of bintrafusp alfa…
Primary Objective:- to assess the effect of chemotherapy given concurrently with pembrolizumab on overall response rate (ORR) in NSCLC patients with high PD-L1 and high tumor burden Secondary Objectives: - to examine the effect of chemotherapy given…
The primary objective of the study of this study is to demonstrate that stroma-targeting by tocilizumab in esophageal adenocarcinoma patients with highly activated stroma increases efficacy of chemoradiotherapy measured by pathological response…